Targeted therapy in advanced colon cancer: The role of new therapies

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Tabernero, J ^a   Salazar, R ^a   Casado, E ^a   Martinelli, E ^a   Gomez P ^a   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY M225; OXALIPLATIN; PELITINIB; PLACEBO; ROFECOXIB; SEMAXANIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON SURGERY; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT FAILURE; TUMOR VASCULARIZATION;

EID: 9744248657     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh905     Document Type: Article

References (48)

1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1S-13S.
2. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92: 1331-1346.
3. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (Abstr 7).
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 252 (Abstr 1012).
5. Hemming AW, Davis NL, Kluftinger A et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51: 147-152.
6. KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12: 1397-1403.
7. Mendelsohn J. Blockade of receptors for growth factors: An anticancer therapy. Clin Cancer Res 2000; 6: 747-753.
8. Liu B, Fang M, Schmidt M et al. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cell lines do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82: 1991-1999.
9. Ciardiello F, Bianco R, Damiano V et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-916.
10. Prewett M, Hooper AT, Bassi R et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Cancer Res 2002; 8: 994-1003.
11. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
12. Saltz L, Meropol NJ, Loehrer PJ et al. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21: 127a (Abstr 504).
13. Lutz MP, Schöffski P, Folprecht G et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol 2002; 13 (Suppl 5): 73.
14. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21: 135a (Abstr 536).
15. Van Laethem J-L, Raoul J-L, Mitry E et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003; 22: 264 (Abstr 1058).
16. Tabernero J, Rojo F, Jimenez E et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22: 192 (Abstr 770).
17. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-184.
18. Meropol NJ, Berlin J, Hecht JR et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 256 (Abstr 1026).
19. Seymour L, Goss G, Stewart D et al. A translational research study of ZD1839 at a dose of 750mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann Oncol 2002; 13 (Suppl 5): 73 (Abstr 264PD).
20. Oza AM, Townsley CA, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 196 (Abstr 785).
21. Cho CD, Fisher GA, Halsey J et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 265 (Abstr 1062).
22. Hanauske AR, Diaz-Rubio E, Cassidy J et al. Erlotinib HCl in combination with FOLFOX-4 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22: 197 (Abstr 789).
23. Salazar R, Koehne CH, Cortes-Funes H et al. Preliminary report of a phase 1/2 open-label study of EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan in patients with advanced colorectal cancer. In Proceedings of the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. Boston, USA: AACR 2003; 80 (Abstr 125).
24. Tomisaki S, Ohno S, Ichiyoshi Y et al. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 1996; 77: 1722-1728.
25. Takebayashi Y, Akiyama S, Yamada K et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-231.
26. Tanigawa N, Amaya H, Matsumura M et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 1043-1046.
27. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
28. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
29. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-1797.
30. Borgström P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19: 4203-4214.
31. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II randomized trial comparing Bevacizumab plus Fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
32. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003; 22: (Abstr 3646).
33. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 1-8.
34. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000; 5 (Suppl 1): 11-15.
35. Fong TAT, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
36. Vajkoczy P, Menger MD, Vollmar B et al. Inhibition of tumor growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1: 31-41.
37. Shaheen RM, Davis DW, Liu W et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412-5416.
38. Shaheen RM, Tseng WW, Davis DW et al. Tyrosine kinase inhibition of multiple angiogenic growth factors receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001; 61: 1464-1468.
39. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
40. Eberhart CE, Coffey RJ, Radhika A et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
41. Sheng H, Shao J, Kirkland SC et al. Inhibition of tumour cell growth by selective inhibition of cyclo-oxygenase-2. J Clin Invest 1997; 99: 2254-2259.
42. Steinbach G, Lynch PM, Philips RK et al. The effect of celecoxib in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
43. Williams CS, Watson AJ, Sheng H et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-6051.
44. Trifan OC, Durham WF, Salazar VS et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effects of CPT-11. Cancer Res 2002; 62: 5778-5784.
45. Lin EH, Morris J, Chau NK et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 138b (Abstr 2364).
46. Blankem CD, Benson AB, Dragovich T et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21: 127a (Abstr 505).
47. Pan C, Loehrer P, Juliar R et al. A phase II study of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer (CRC): A Hoosier Oncology Group Study. Proc Am Soc Clin Oncol 2003; 22: 335 (Abstr 1347).
48. Becerra CR, Frenkel EP, Gaynor R et al. A phase II study of 5-fluorouracil (5-FU) and leucovorin calcium (LV) plus open-label rofecoxib in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: 107b (Abstr 2240).